A Superdevice for Mental Health🔒 SSL Verified

Table of Contents

• ↓ Optimizing Brain Function
• ↓ Proof-of-Concept
• ↓ Leadership
• ↓ Kelly Roman
• ↓ Chip Fisher
• ↓ Advisors
• ↓ Top Alternatives to fisherwallace.com

6-Month Traffic Trend Estimate

Official Contact & Profiles

Visual representation extracted from fisherwallace.com

Content Snippets from fisherwallace.com

"The result of 17 years of clinical research and product development, millions of hours of real-world testing, and a groundbreaking collaboration with the team behind Beats and Nest, OAK is the first prescription brain stimulation device designed for population-scale. We anticipate initial FDA clearance for anxiety treatment in Q3 2026 and are advancing towards insomnia, depression, and human performance indications in 2027. Our tech is currently being pilot tested in the U.S. Department of Veterans Affairs. Our company is primarily funded by thousands of early adopters of our proof-of-concept device. We invite you to become an investor through our SEC-regulated equity crowdfunding campaign as we pursue FDA clearance."

"In 2025, researchers at Harvard Medical School and Massachusetts General Hospital modeled the strength of our device's neurostimulation in the brain,  demonstrating that it significantly engages structures that govern to mood, sleep, autonomic function, and cognitive resilience. Clinical studies enrolling nearly 2000 participants in total demonstrate safety, comfort, and rapid effectiveness in treating anxiety, depression, and insomnia, as well as bipolar II depression and symptoms of Parkinson's."

"Our recently submitted FDA clearance application for the treatment of anxiety includes a real-world study of 164 first responders, conducted in collaboration with the Seattle Police Department, Washington State University, and other first responder organizations. The study showed rapid anxiety symptom reduction that continued to improve over the eight-week study period."

"As the FDA undertook a multi-year process of determining how our category would be regulated, we were able to distribute our proof-of-concept technology to tens of thousands of patients, through thousands of prescribers. This enabled us to refine our technology and usage protocol with valuable real-world user feedback in a way that would be impossible to replicate today. The new FDA regulation elevates the credibility of the category by requiring clinical trial evidence to support each intended use. We are now awaiting FDA’s decision on our first application submitted under the new regulation."

Key Topics & Focus Areas for fisherwallace.com:

Optimizing Brain Function

Proof-of-Concept

Leadership

Kelly Roman

Chip Fisher

Advisors